Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

JAPANESE - Skin Toxicity Evaluation Protocol With Panitumumab as 3rd line treatment for Colorectal Cancer(J-STEPP),(HGCSG1001)

ABSTRACT: Interventions: panitumumab+skin moisturizers(8weeks) panitumumab+skinmoisturizers+sunscreen+minocycline+topical steroid(8weeks) Primary outcome(s): Adverce event of skin toxicity (>= grade2) during the 6 weeks from treatment started Study Design: Parallel Randomized

DISEASE(S): Unresectable Advanced Colorectal Cancer

PROVIDER: 2620326 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Skin Toxicity Prevention Protocol with Panitumumab treatment for Metastatic Colorectal Cancer

Project description:Interventions: A group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care+antibiotics Clarithromycin is administered orally twice a day B group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care only Primary outcome(s): incidence rates of skin toxicity (>=Grade2) with or without antibiotics during the 6 weeks from the treatment started Study Design: Parallel Randomized

| 2626856 | ecrin-mdr-crc

A phase 2 study, investigating prevention and treatment algorism of the skin toxicity related with Panitumumab treatment in patients with unresectable and/or metastatic CRC with KRAS wild type refractory to 5-FU containing chemotherapy

Project description:Interventions: pre-emptive administration of minocycline hydrochloride 100mg twice per day and consistent heparinoid containing skin moisturizer, which are started at panitumumab contained chemotherapy started. And reactive treatment of topical steroid; Hydrocortisone butyrate cream 0.1% apply to face, diflupredonate ointment 0.05% apply to the other part. Primary outcome(s): incidence rates and timing of grade two or more skin toxicity during 6 weeks from Panitumumab contained chemotherapy started. Study Design: Single arm Non-randomized

| 2621298 | ecrin-mdr-crc

Multicenter phase II trial of panitumumab plus irinotecan and S-1 (PIRIS regimen) in patients treated by oxaliplatin-based chemotherapy with K-RAS wild-type advanced colorectal cancer.

Project description:Interventions: Take care of skin before the PIRIS regimen (moistureizer,sunscreen,steroid, antibiotic). Day1/Day15 panitumumab 6mg/kg irinotecan 125mg/m2 Day1~14 S-1 80-120mg/m2 q4w(until progressive disease) Primary outcome(s): Response ratte : RR Study Design: Single arm Non-randomized

| 2620021 | ecrin-mdr-crc

Expression data from human skin exposed to solar-simulated radiation with or without sunscreen

2011-10-19 | GSE22083 | GEO

Expression data from human skin exposed to solar-simulated radiation with or without sunscreen

Project description:Despite widespread use of sunscreens that minimize erythema by blocking ultraviolet B (UVB) radiation, incidence rates of melanoma continue to rise. In considering this disparity between intervention and disease prevalence, we investigated the in vivo transcriptome of human skin treated with sunscreen and solar-simulated radiation (ssR). A focal skin area of healthy participants was exposed to ssR at 1 minimal erythema dose (MED), 0.1 MED or 100 J/m2 with or without prior application of sunscreen, or to non-UVB-spectrum of ssR (solar-simulated UVA/visible/infrared radiation: ssA). Skin biopsies were analyzed using expression microarrays. Ninety-eight microarrays from 14 healthy human volunteers were analyzed. Focal skin areas of all 14 volunteers were exposed to 0 J/m2, 100 J/m2, 1 minimal erythema dose (MED), and 0.1 MED of solar-simulated radiation (ssR). Eight of the 14 volunteers (Group 1) were also exposed to ssA (ssR minus UVB) that were generated by removing UVB from 0 J/m2, 100 J/m2, 1 minimal erythema dose (MED), and 0.1 MED of ssR. Additionally, 6 of the 14 volunteers (Group 2) were treated with sunscreen of sun protection factor (SPF) 15, and exposed to 0 J/m2, 100 J/m2, 1 minimal erythema dose (MED), and 0.1 MED of ssR. Biopsy was taken 24 hours after exposure from each focal skin area for RNA extraction.

2011-10-18 | E-GEOD-22083 | biostudies-arrayexpress

Expression data from mouse abdominal skin

Project description:Psoriasis-like skin inflammation was indused by 5 daily topical applications of imiquimod (IMQ), a TLR7/8 agonist, or vehicle, in mice fed a high fat diet (HFD) or control chow diet (CD). Skin samples were collected at day 6.

2019-06-30 | GSE68750 | GEO

Distinct activation of positive and negative regulatory immune genes during an evolving T cell response to diphencyprone (DPCP) in human skin

Project description:We sought to characterize delayed-type hypersensitivity (DTH) responses elicited by topical hapten DPCP in normal human skin Comparison of transcriptomes among DPCP- and placebo-treated skin at different time points

2014-03-29 | E-GEOD-52360 | biostudies-arrayexpress

Expression data from IMQ-induced psoriasis-like skin inflammation in miR-146a-/- and C57BL6J mice

Project description:miR-146a acts as a negative feedback regulator of inflammation. To investigate the role of miR-146a in psoriasis psoriasiform skin inflammation was indeuced in Mir-146a-/- and wild type mice (C57BL6J) by topical applciation of imiquimod (IMQ)-cream (Aldara). Gene expression profiling (Affymetrix) was used to identify transcriptomic changes associated with psoriasis-like skin inflammation in wild type vs. miR-146a -/-mice. A daily topical dose of 31.25 mg of Aldara cream (5% IMQ) was applied on the right ear of miR-146a -/- and C57BL/6 mice on three consecutive days to induce psorisis-like skin inflammation. Mice were sacrificed at day 4. Ear flaps were collected for total RNA extraction and hybridization on Affymatrix GeneTitan plate format Gene ST 2.1 (mouse).

2016-02-19 | E-GEOD-78057 | biostudies-arrayexpress

Transcriptomal analysis of mouse healthy skin sample and of DMBA/TPA-induced skin Tumor

Project description:In this analysis we plan to identify the genes that are differentially expressed during the development of skin carcinoma (SCC) subsquent to the chronic and topical application of a carcinogene agent (DMBA) and a tumor promoter (TPA)

2017-06-07 | GSE89462 | GEO